$13.500
+0.964 (+7.14%)Zum Schluss
- High
- 14.800
- Open
- 14.000
- VWAP
- 13.53
- Vol
- 19.48K
- Mkt Cap
- —
- Low
- 12.301
- Amount
- 263.70K
- EV/EBITDA, TTM
- 0.00
Channel Therapeutics Corporation is engaged in developing innovative, non-addictive, drugs to treat chronic neuropathic and acute and chronic eye pain. The Company is focused on the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. It is initially targeting orphan chronic pain indications, specifically small fiber neuropathy and erythromelalgia, and acute and chronic eye pain. The Company’s patented, selective, and potent (nM) inhibitor of human NaV1.7 has demonstrated additional efficacy in several models of pain: acute, chronic, inflammatory, visceral, post-surgical, and chemotherapy-induced.
Bewertungskennzahlen
Event-Zeitleiste
News
5.007-10BenzingaPelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease
8.507-02NASDAQ.COMLigand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In July
8.507-02NewsfilterPelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
2.006-29TipRanksUpcoming Stock Splits This Week (June 30 to July 4) – Stay Invested
8.506-27BenzingaWhy Is Channel Therapeutics Stock Surging On Friday?
CHRO FAQ — answered by Alphio AI
Channel Therapeutics Corporation is engaged in developing innovative, non-addictive, drugs to treat chronic neuropathic and acute and chronic eye pain. The Company is focused on the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. It is initially targeting orphan chronic pain indications, specifically small fiber neuropathy and erythromelalgia, and acute and chronic eye pain. The Company’s patented, selective, and potent (nM) inhibitor of human NaV1.7 has demonstrated additional efficacy in several models of pain: acute, chronic, inflammatory, visceral, post-surgical, and chemotherapy-induced. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.